A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

NCT04049825 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions

DRUG: OPB-111077
DRUG: OPB-111077

Sponsor

Otsuka Pharmaceutical Co., Ltd.